| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:1113.)
© 2003 American Heart Association, Inc.
Basic Science Reports |
From the Immunobiology Research Center, Department of Surgery and Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
Correspondence to Christiane Ferran, MD, PhD, Immunobiology Research Center, 99 Brookline Ave, Boston MA 02215. E-mail cferran{at}caregroup.harvard.edu
Received June 26, 2002; de novo received December 31, 2002; revision received April 22, 2003; accepted May 20, 2003.
Background CD40/CD40 ligand (CD40L) signaling is a potent activator of endothelial cells (ECs) and promoter of atherosclerosis. In this study, we investigate whether A20 (a gene we have shown to be antiinflammatory and antiapoptotic in ECs) can protect from CD40/CD40L-mediated EC activation.
Methods and Results Overexpression of CD40, in a transient transfection system, activates the transcription factor NF-
B and upregulates I
B
, E-selectin, and tissue factor (TF) reporter activity. Coexpression of A20 inhibits NF-
B and upregulation of I
B
and E-Selectin but not TF, suggesting that CD40 induces TF in a nonNF-
Bdependent manner. In human coronary artery ECs (HCAECs), adenovirus-mediated overexpression of A20 blocks physiological, CD40-induced activation of NF-
B, upstream of I
B
degradation (Western blot) and subsequently upregulation of ICAM-1, VCAM-1, and E-selectin (flow cytometry). Although A20 does not block TF transcription its expression in HCAECs inhibits TF induction (colorimetric assay and RT-PCR) by blunting CD40 upregulation. We demonstrate that CD40 signaling induces apoptosis in a proinflammatory microenvironment. A20 overexpression protects from CD40-mediated EC apoptosis (DNA content analysis and trypan blue exclusion). We also demonstrate that signaling through CD40L activates NF-
B and induces apoptosis in ECs, both of which are inhibited by A20 overexpression.
Conclusion A20 works at multiple levels to protect ECs from CD40/CD40L mediated activation and apoptosis. A20-based therapy could be beneficial for the treatment of vascular diseases such as atherosclerosis and transplant-associated vasculopathy.
Key Words: endothelium atherosclerosis gene therapy thrombosis inflammation
This article has been cited by other articles:
![]() |
V. I. Patel, S. Daniel, C. R. Longo, G. V. Shrikhande, S. T. Scali, E. Czismadia, C. M. Groft, T. Shukri, C. Motley-Dore, H. E. Ramsey, et al. A20, a modulator of smooth muscle cell proliferation and apoptosis, prevents and induces regression of neointimal hyperplasia FASEB J, July 1, 2006; 20(9): 1418 - 1430. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Laxmanan, D. Datta, C. Geehan, D. M. Briscoe, and S. Pal CD40: A Mediator of Pro- and Anti-Inflammatory Signals in Renal Tubular Epithelial Cells J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2714 - 2723. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li and E. P. Nord CD40/CD154 ligation induces mononuclear cell adhesion to human renal proximal tubule cells via increased ICAM-1 expression Am J Physiol Renal Physiol, July 1, 2005; 289(1): F145 - F153. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |